{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DNA+vaccine+placebo",
    "query": {
      "intervention": "DNA vaccine placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 68,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DNA+vaccine+placebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T06:24:08.306Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03755713",
      "title": "A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "ASP0892",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 20,
      "start_date": "2019-03-12",
      "completion_date": "2021-10-11",
      "has_results": false,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-09-29T06:24:08.306Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03755713"
    },
    {
      "nct_id": "NCT01764256",
      "title": "A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rotavirus Infection"
      ],
      "interventions": [
        {
          "name": "P2-VP8 subunit rotavirus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "PATH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2012-12",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2019-03-12",
      "last_synced_at": "2026-09-29T06:24:08.306Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01764256"
    },
    {
      "nct_id": "NCT00908323",
      "title": "Early Immune Responses to Vaccination - A Substudy to HVTN 205",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "JS7 DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA/HIV62 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 47,
      "start_date": "2009-07",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-09-29T06:24:08.306Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Seattle, Washington",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00908323"
    },
    {
      "nct_id": "NCT04927585",
      "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "env (A,B,C,A/E)/gag (C) DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp120 (A,B,C,A/E) Protein Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-SE adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Worcester HIV Vaccine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 42,
      "start_date": "2021-07-08",
      "completion_date": "2023-12-07",
      "has_results": false,
      "last_update_posted_date": "2024-04-09",
      "last_synced_at": "2026-09-29T06:24:08.306Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04927585"
    },
    {
      "nct_id": "NCT01190176",
      "title": "Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infections, Papillomavirus"
      ],
      "interventions": [
        {
          "name": "Gynaecological follow-up",
          "type": "PROCEDURE"
        },
        {
          "name": "Cervarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo control",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "28 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "28 Years and older · Female only"
      },
      "enrollment_count": 34,
      "start_date": "2011-09-12",
      "completion_date": "2017-09-20",
      "has_results": true,
      "last_update_posted_date": "2019-10-30",
      "last_synced_at": "2026-09-29T06:24:08.306Z",
      "location_count": 3,
      "location_summary": "Iowa City, Iowa • Wichita, Kansas • Wenatchee, Washington",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Wenatchee",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01190176"
    },
    {
      "nct_id": "NCT00141024",
      "title": "Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "EP HIV-1043",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EP HIV-1090",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 84,
      "start_date": "2006-01",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-09-29T06:24:08.306Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Baltimore, Maryland • Rochester, New York",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141024"
    },
    {
      "nct_id": "NCT03409276",
      "title": "Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "env (A,B,C,A/E)/gag (C) DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp120 (A,B,C,A/E) Protein Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-SE adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": "2018-03-16",
      "completion_date": "2020-10-22",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-09-29T06:24:08.306Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03409276"
    },
    {
      "nct_id": "NCT01423825",
      "title": "Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Sub C gp140 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59C.1 Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 27,
      "start_date": "2011-08",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-09-29T06:24:08.306Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01423825"
    },
    {
      "nct_id": "NCT04642638",
      "title": "Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Infection",
        "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",
        "COVID-19 Disease"
      ],
      "interventions": [
        {
          "name": "INO-4800",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA® 2000",
          "type": "DEVICE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1307,
      "start_date": "2020-11-30",
      "completion_date": "2022-09-13",
      "has_results": true,
      "last_update_posted_date": "2023-12-20",
      "last_synced_at": "2026-09-29T06:24:08.306Z",
      "location_count": 16,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04642638"
    },
    {
      "nct_id": "NCT03181789",
      "title": "Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "p24CE1/2 pDNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "p55^gag pDNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-12 pDNA Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2017-10-18",
      "completion_date": "2020-04-29",
      "has_results": true,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-09-29T06:24:08.306Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Decatur, Georgia • Cleveland, Ohio",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03181789"
    }
  ]
}